Abarceo Pharma
Abarceo is a preclinical stage company, a spinout of Lund University Diabetes Center. The company has expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes and has identified a novel diabetes target responsible for the dysfunction, VDAC-1. By blocking VDAC-1 with a small molecule blocker beta cells are returned to a functional state in a durable and disease modifying manner allowing patients to produce sufficient insulin, naturally. The company is fundraising to support preclinical development.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
10
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
1
tools in use
Monthly traffic
1
organic / mo
Sign up free to see all 1 verified contacts at Abarceo Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Abarceo Pharma
1 distinct titles indexed · top 1 shown.
- 1chief executive officer
Sign up to unlock all 1 contacts at Abarceo Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Abarceo Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.